Journal article · 2026 · Open access

Triple Combination Therapy: A Promising Path Forward against β-Lactamase-Mediated Resistance

Nakita Reddy, José Rogério A. Silva, Per I. Arvidsson, Hendrik Gerhardus Kruger, Thavendran Govender, Tricia Naicker

Journal of Medicinal Chemistry, 69(20), 23075–23091 · Published 3 October 2026 · DOI 10.1021/acs.jmedchem.6c00399

Open PDFView at the publisherCite this paper

In brief

“Triple Combination Therapy: A Promising Path Forward against β-Lactamase-Mediated Resistance” is a 2026 journal article by Nakita Reddy and 5 co-authors, published in Journal of Medicinal Chemistry. OpenAlex counts 3 citations as of 16 November 2026, which puts it in the top 4% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at Journal of Medicinal Chemistry.

Citations
3
Most cited in
2026 (3)
Field-weighted impact
6.88
References
119
Authors
6

Abstract

The silent pandemic of antimicrobial resistance (AMR) continues to drive global morbidity and mortality. Resistance is often mediated by co-expression of serine β-lactamases (SBLs) and metallo-β-lactamases (MBLs), limiting treatment options. While several SBL inhibitors are clinically available, MBL inhibitors are yet to reach the market, and only a few candidates are in late-stage development. Dual-β-lactamase inhibitors remain an unmet goal. To preserve existing antibiotics, alternative strategies are required. This perspective highlights triple combination therapy comprising a β-lactam antibiotic, an SBL inhibitor, and an MBL-targeting agent to achieve broader coverage. Notably, in 2025, the U.S Food and Drug Administration (FDA) has approved aztreonam-avibactam (Emblaveo), in combination with metronidazole, for adults with complicated intra-abdominal infections who have limited or no alternative treatment options. Expanding such strategies may help mitigate AMR and support ongoing antimicrobial development efforts.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Reddy, N., Silva, J. R. A., Arvidsson, P. I., Kruger, H. G., Govender, T., & Naicker, T. (2026). Triple Combination Therapy: A Promising Path Forward against β-Lactamase-Mediated Resistance. Journal of Medicinal Chemistry, 69(20), 23075–23091. https://doi.org/10.1021/acs.jmedchem.6c00399

MLA 9

Reddy, Nakita, et al. “Triple Combination Therapy: A Promising Path Forward against β-Lactamase-Mediated Resistance.” Journal of Medicinal Chemistry, vol. 69, no. 20, 2026, pp. 23075–23091. https://doi.org/10.1021/acs.jmedchem.6c00399.

Chicago

Reddy, Nakita, José Rogério A. Silva, Per I. Arvidsson, Hendrik Gerhardus Kruger, Thavendran Govender, and Tricia Naicker. 2026. “Triple Combination Therapy: A Promising Path Forward against β-Lactamase-Mediated Resistance.” Journal of Medicinal Chemistry 69 (20): 23075–23091. https://doi.org/10.1021/acs.jmedchem.6c00399.

Harvard

Reddy, N. et al. (2026) ‘Triple Combination Therapy: A Promising Path Forward against β-Lactamase-Mediated Resistance’, Journal of Medicinal Chemistry, 69(20), pp. 23075–23091. doi:10.1021/acs.jmedchem.6c00399.

IEEE

N. Reddy, J. R. A. Silva, P. I. Arvidsson, H. G. Kruger, T. Govender, and T. Naicker, “Triple Combination Therapy: A Promising Path Forward against β-Lactamase-Mediated Resistance,” Journal of Medicinal Chemistry, vol. 69, no. 20, pp. 23075–23091, 2026, doi: 10.1021/acs.jmedchem.6c00399.

BibTeX

@article{reddy2026triple,
  title     = {{Triple Combination Therapy: A Promising Path Forward against β-Lactamase-Mediated Resistance}},
  author    = {Reddy, Nakita and Silva, José Rogério A. and Arvidsson, Per I. and Kruger, Hendrik Gerhardus and Govender, Thavendran and Naicker, Tricia},
  journal   = {Journal of Medicinal Chemistry},
  year      = {2026},
  volume    = {69},
  number    = {20},
  pages     = {23075--23091},
  doi       = {10.1021/acs.jmedchem.6c00399},
  url       = {https://doi.org/10.1021/acs.jmedchem.6c00399}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria

  • triple combination therapy
  • beta-lactamase inhibitors
  • serine beta-lactamases
  • metallo-beta-lactamase
  • antimicrobial resistance
  • aztreonam-avibactam
  • metronidazole
  • complicated intra-abdominal infections

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Reddy, N., Silva, J. R. A., Arvidsson, P. I., Kruger, H. G., Govender, T., & Naicker, T. (2026). Triple Combination Therapy: A Promising Path Forward against β-Lactamase-Mediated Resistance. Journal of Medicinal Chemistry, 69(20), 23075–23091. https://doi.org/10.1021/acs.jmedchem.6c00399

How many times has this paper been cited?

3 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Journal of Medicinal Chemistry: sign in and open the PDF from this page.

Who wrote this paper?

Nakita Reddy, José Rogério A. Silva, Per I. Arvidsson, Hendrik Gerhardus Kruger, Thavendran Govender, Tricia Naicker.

What is the DOI of this paper?

10.1021/acs.jmedchem.6c00399, permanently at https://doi.org/10.1021/acs.jmedchem.6c00399. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.